Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Pembrolizumab vs Chemotherapy in Untreated Advanced Urothelial Carcinoma
NCT05911295Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 24
01
Overview
A Phase 3 trial of disitamab vedotin in urothelial carcinoma (UC), sponsored by Pfizer. Started Sep 2023; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05911295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911295.